Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.
NCT01931982 on ClinicalTrials.gov · last registry update 2014-06-25
A small phase 4 — 20 participants, against a typical 75. The sponsor logged completion for April 2014. Primary outcome, as filed: Change in coronary flow reserve (CFR). liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Bispebjerg Hospital
- Sponsor type
- Other
- Enrollment
- 20
- Started
- 2013-05
- Primary completion
- 2014-04 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in coronary flow reserve (CFR)
Conditions studied
Type 2 Diabetes · Microvascular Dysfunction
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.